What Is DSIP? A Peptide With an Unresolved Mechanism

Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.

Most peptide profiles can be written as a mechanism: here is the receptor, here is the pathway, here is the evidence. DSIP cannot. The honest version of this article is that a peptide isolated in the 1970s still has no established receptor, and the most cited review of it — published in the Journal of Neurochemistry in 2006 — carries the subtitle “a still unresolved riddle”. That is the most useful thing anyone can tell you about it, and it is where any serious reading has to begin.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

The molecule

Property	Value
Sequence	Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Length	9 residues
Disulfide bridges	None
Non-natural residues	None
C-terminus	Free acid
Net charge character	Acidic — two carboxylate side chains
Established receptor	None

Chemically, DSIP is among the plainest peptides in a research catalogue. Three glycines and two alanines out of nine residues make it conformationally flexible; the aspartate and glutamate make it acidic, which affects its chromatographic behaviour and its solubility profile. There is no stabilising modification of any kind. The single tryptophan at position 1 is the only residue requiring particular care in handling.

That plainness is itself informative. Peptides that signal through a high-affinity receptor usually show some structural distinctiveness — a constrained ring, an unusual residue, a modified terminus. DSIP has none, which is consistent with the difficulty the field has had identifying a target.

How it was found, and why the name stuck

DSIP was isolated from cerebral venous blood of rabbits in work that used an electroencephalographic readout: the fraction being purified was associated with a change in slow-wave activity. The peptide was named after that observation.

This matters because the name encodes a hypothesis, not a finding. It describes what the isolation assay measured in one animal preparation in the 1970s. The field has had five decades to confirm a mechanism behind that observation and has not done so. When a compound’s name presupposes its function, the literature tends to inherit the presupposition, and a careful reader has to separate the two.

The review literature, read in sequence

Review	Year	What it represents
Graf, Neurosci Biobehav Rev	1984	The first consolidation, roughly a decade after isolation
Graf, Peptides	1986	An update two years later from the same group
Pollard, Eur J Anaesthesiol	2001	A later survey from an anaesthesia perspective
Kovalzon, J Neurochem	2006	The “unresolved riddle” assessment

Reading these four in order is a genuinely instructive exercise, and it is the main thing we would recommend to anyone evaluating this compound. The trajectory is not one of accumulating mechanism. It is a sequence of careful summaries of observations that were never unified, ending in an explicit acknowledgement that the question remains open. A field does not publish a review titled “a still unresolved riddle” thirty years after isolation if the mechanism is in hand.

Later work took a different direction. A 2009 review in Obesity Reviews considered a possible link between DSIP and glucocorticoid-induced leucine zipper in the context of circadian mechanisms. That is a hypothesis-generating connection rather than an established pathway, and it should be read as such, but it illustrates that the peptide has not been abandoned.

What this means for a laboratory

A compound without an established receptor is not useless, but it constrains what an experiment can claim.

Mechanistic controls are unavailable. There is no receptor antagonist, no knockout, no competitive ligand. An observed effect therefore cannot be attributed to a pathway.
Negative controls carry more weight than usual. A scrambled-sequence peptide of identical composition is the minimum comparator, because without receptor-level controls it is the only way to argue the sequence matters.
Published effect sizes should be treated cautiously. Observations that have not been mechanistically explained in five decades have, in many cases, also not been robustly replicated.
The identity of the material matters disproportionately. With no bioassay that is reliable and no receptor binding assay available, analytical confirmation is the only check on what is in the vial. See how to read a certificate of analysis.

Handling

The N-terminal tryptophan is the main chemical liability, and the acidic character affects solubility behaviour.

Store sealed lyophilized powder at −20 °C, protected from light. A single tryptophan is still a photo-oxidation target.
An acidic peptide may dissolve poorly in a strongly acidic diluent; check the certificate’s solubility note rather than assuming water is optimal.
Aspartate- and glycine-containing sequences are candidates for deamidation and isomerisation over long storage in solution, so aliquot and use promptly. See storing reconstituted peptides.
Calculate concentration from net peptide mass, not vial weight. Our reconstitution calculator takes the molecular weight and net content from the certificate.

Our DSIP research material is supplied for laboratory research use. Certificates are available for listed products — contact us for the latest report.

Scope note

This material is supplied for laboratory research use only. It is not a medicine, not a supplement, and not for human or veterinary use. This article describes sequence, history and the state of the published literature.

Open questions

Does DSIP have a receptor, and if not, how are the original electrophysiological observations to be explained?
Have the 1970s findings been replicated under modern conditions with characterised material?
Is the circadian and endocrine connection proposed in later reviews supported by primary data?

Frequently asked questions

What is DSIP?

Delta sleep-inducing peptide is a nonapeptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, isolated in the 1970s from rabbit cerebral venous blood. The name describes the electroencephalographic observation that led to its isolation, not an established mechanism.

Is DSIP's mechanism of action known?

No. A 2006 review in the Journal of Neurochemistry is titled “a still unresolved riddle”, and that remains an accurate summary. No receptor has been established, which is unusual for a peptide isolated five decades ago.

Why is the name misleading?

The name encodes the assay that produced it. DSIP was identified by an electrophysiological observation in an animal preparation, and the name fixed that interpretation in place before a mechanism was found. The literature since has not settled what the peptide does.

Does DSIP have any unusual chemical features?

It is strikingly plain: nine residues, no disulfide bridge, no D-amino acids, no amidation, and a high proportion of glycine and small residues. The only notable residue is the N-terminal tryptophan, which is oxidation-prone.

Why is DSIP still studied?

Partly because the original observations were never explained and partly because later work connected the peptide to circadian and endocrine questions. The 2009 review linking DSIP to glucocorticoid-induced leucine zipper is an example of that second direction.

References

Kovalzon VM, et al. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006. PMID: 16539679 https://pubmed.ncbi.nlm.nih.gov/16539679/
Graf MV, et al. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984. PMID: 6145137 https://pubmed.ncbi.nlm.nih.gov/6145137/
Graf MV, et al. Delta-sleep-inducing peptide (DSIP): an update. Peptides. 1986. PMID: 3550726 https://pubmed.ncbi.nlm.nih.gov/3550726/
Pollard BJ, et al. Delta sleep-inducing peptide. Eur J Anaesthesiol. 2001. PMID: 11437870 https://pubmed.ncbi.nlm.nih.gov/11437870/